Silexion Therapeutics Ltd. (SLXN) Stock

Silexion Therapeutics Ltd. (SLXN) is a Healthcare stock trading at $2.75 (as of 2026-06-18), with a market capitalization of $891933.00 and a trailing P/E of 0.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Silexion Therapeutics Ltd. is a biopharmaceutical company developing RNA interference (RNAi) cancer therapies and related delivery systems for malignant solid tumors. Its LODER delivery platform supports programs including SiG12D-LODER (pancreatic cancer), Prostate-LODER (prostate cancer), and GBM-LODER (glioblastoma), which are in pre-clinical and early clinical stages.

Valuation — source: SEC EDGAR (first-party)
Price	$2.75
Market Cap	$891933.00
P/E Ratio	0.5
EV / EBITDA	-1.1
Price / Book	56.20
DCF Value (model)	$-53.52
DCF Upside vs Price	-2046.2%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$155000.00
Net Margin	-7685.2%
Return on Equity	-4436.4%
Current Ratio	1.00
Revenue Growth (YoY)	1500.0%
EPS Growth (YoY)	226.9%
FCF Growth (YoY)	48.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-14.17 (distress)

Valuation vs Sector & Industry
Stock P/E	0.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-97.5%
vs Industry	-97.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	CITADEL ADVISORS LLC ($26785.00)
Institutional Holders Tracked	8

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Ilan Hadar
Employees	11
Country	IL
IPO Date	2024-08-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.